Ontario first Canadian province to pay for Venclexta

The Province of Ontario has become Canada’s first to reimburse Venclexta (venetoclax) monotherapy under its Drugs and Devices Division's (DDD) Exceptional Access Program.

Venclexta, from US drugmaker AbbVie (NYSE: ABBV) and Swiss pharma giant Roche (ROG: SIX), is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have no other treatment options.

This listing follows the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA) earlier this year.